Comparative Pharmacology
Head-to-head clinical analysis: BENICAR HCT versus LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BENICAR HCT versus LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE.
BENICAR HCT vs LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of an angiotensin II receptor blocker (ARB) and a thiazide diuretic. Olmesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively antagonizing the AT1 receptor. Hydrochlorothiazide inhibits the sodium-chloride symporter in the distal convoluted tubule, increasing excretion of sodium, chloride, and water, thereby reducing plasma volume.
Losartan is an angiotensin II receptor blocker (ARB) that selectively antagonizes AT1 receptors, blocking vasoconstriction and aldosterone secretion. Hydrochlorothiazide is a thiazide diuretic inhibiting sodium and chloride reabsorption in the distal convoluted tubule, reducing plasma volume and peripheral resistance.
One tablet orally once daily. Available strengths: 40 mg olmesartan / 12.5 mg hydrochlorothiazide, 40 mg olmesartan / 25 mg hydrochlorothiazide. Dose may be titrated after 2-4 weeks based on response.
Initial: losartan 50 mg/hydrochlorothiazide 12.5 mg orally once daily. Titrate to maximum losartan 100 mg/hydrochlorothiazide 25 mg once daily. Usual maintenance: losartan 50-100 mg/hydrochlorothiazide 12.5-25 mg once daily.
None Documented
None Documented
Olmesartan: Terminal elimination half-life is 10-15 hours, supporting once-daily dosing. Hydrochlorothiazide: Terminal half-life is 5.6-14.8 hours (mean ~10 hours), prolonged in renal impairment.
Losartan: 2 hours; Active metabolite E-3174: 6-9 hours. Hydrochlorothiazide: 6-15 hours (mean 10 hours) with prolonged elimination in renal impairment.
Olmesartan: Approximately 50-65% of absorbed dose excreted in urine (10-20% as unchanged drug, remainder as metabolites), 35-50% in feces via biliary excretion. Hydrochlorothiazide: ≥95% excreted renally as unchanged drug.
Losartan: 35% renal, 60% biliary/fecal; Hydrochlorothiazide: >95% renal (tubular secretion).
Category C
Category D/X
ARB + Thiazide Diuretic
ARB